HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA guidance agenda

This article was originally published in The Rose Sheet

Executive Summary

Draft guidance requiring warning statements for cosmetics with insufficient data to substantiate safety included on FDA's annual guidance agenda published in the Federal Register April 4. Cosmetics Handbook for Industry guidance also was included. Agency is soliciting comments on the agenda. FDA released draft guidance for alpha-hydroxy acid-containing cosmetics in December (1"The Rose Sheet" Dec. 9, 2002, p. 3)...

You may also be interested in...



Interim AHA Labeling Guidance Proposed By FDA Pending NTP Study Results

FDA's draft guidance for labeling of alpha hydroxy acid-containing products is an interim step taken while the agency continues to evaluate AHAs and their impact on increased skin sensitivity to the sun, FDA says in a Dec. 2 1Federal Register notice

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

UsernamePublicRestriction

Register

RS011102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel